Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
The internal test score of Samsung Exynos 2700 surpasses the Qualcomm flagship by about 20%.

The internal test score of Samsung Exynos 2700 surpasses the Qualcomm flagship by about 20%.

智通财经智通财经2026/10/25 01:50
Show original
According to South Korean media outlet Chosun Ilbo, Samsung Electronics is currently developing the mobile application processor (AP) “Exynos 2700”, which has reportedly outperformed Qualcomm (QCOM.US)’s latest flagship product in internal performance evaluations. This chip is expected to be equipped in the “Galaxy S27” series, set to be released early next year. According to news from the electronics industry on the 25th, when tested using the Xiaomi “Xiaomi 18 Pro Max”, the Exynos 2700 achieved a multi-core CPU score of approximately 13,000 on the Geekbench 6.5 benchmark, about 20% higher than the approximately 11,000 points of Qualcomm’s “Snapdragon 8 Elite Extreme 6th generation”. It also leads by around 15% under the Geekbench 7.0 benchmark. Compared with the sub-flagship “Snapdragon 8 Elite 6th generation” equipped in the “Xiaomi 18 Pro”, the scores were higher by 44% and 36% respectively in both tests.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%

Researchers combined Amgen's Imdelltra with AstraZeneca's Imfinzi and found that for patients with aggressive lung cancer whose tumors had already spread, this combination extended survival by about eight months compared to Imfinzi monotherapy. Small cell lung cancer is one of the cancer types with the worst prognosis.

智通财经•2026/10/25 02:56
Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%